Obesity & Weight Regulation

Citation model. Claims grounded in AllNutrition's trust-scored library carry an inline bracketed reference [n] linking to the References section, which lists each source's evidence level and AllNutrition trust score (0–1). Where an AllNutrition query returned an overall evidence_strength and consensus_level, those labels are surfaced in the Evidence Review so readers can calibrate confidence. Only sources actually returned by the tool are cited; no trust scores are invented.

---

1. Introduction

Obesity is the paradigmatic disease of energy homeostasis: a chronic, relapsing condition in which redundant, tightly coupled neuroendocrine circuits defend an elevated level of body fat against both environmental pressure to gain and therapeutic pressure to lose. For decades, clinical teaching reduced obesity to a failure of willpower — "calories in, calories out" as a matter of choice. That framing collapses under the biology. The hypothalamus, gut, and adipose organ constitute an integrated physiological system that actively resists weight loss through redundant hormonal, autonomic, and behavioral mechanisms, and current guidelines now formally define obesity as a chronic disease of adiposity-based organ dysfunction rather than a lifestyle failing [37][39].

This module has two aims. First, to give the physiologic vocabulary — melanocortin signaling, adipokines, ectopic fat, adaptive thermogenesis — needed to explain to a patient why weight regain is a biological event, not a moral one. Second, to synthesize the clinical evidence on dietary, pharmacologic, and surgical management, with particular attention to a finding that recurs throughout the nutrition literature: macronutrient composition explains far less variance in weight-loss outcomes than adherence does. The last decade has also reshaped this field with incretin pharmacotherapy (semaglutide, tirzepatide), which produces weight loss that rivals bariatric surgery and forces a rethinking of the nutritionist's role — not as the primary lever for weight loss, but as the guardian of lean mass and micronutrient adequacy during aggressive pharmacologic loss.

2. Learning Objectives

By the end of this module, the learner will be able to:

1. Describe the hypothalamic melanocortin system (POMC/AgRP neurons), leptin and insulin signaling, and gut-hormone input (GLP-1, PYY, ghrelin, CCK) that together constitute the homeostatic control of energy balance.
2. Differentiate white, brown, and beige adipose tissue by function, and explain the "adipose expandability" model of ectopic fat deposition and its link to insulin resistance.
3. Explain the biology of weight regain — metabolic adaptation, hormonal shifts, and persistent hunger — and why it undermines a rigid "set point" framing in favor of a "settling point"/defended-range model.
4. Critically evaluate the comparative evidence on dietary approaches to weight loss (low-carbohydrate vs. low-fat, Mediterranean, very-low-calorie, meal timing, protein) and articulate why adherence, not macronutrient ratio, is the dominant determinant of outcomes in most trials.
5. Summarize the efficacy, safety, and nutritional co-management priorities of GLP-1/GIP receptor agonist pharmacotherapy, and the nutritional context of bariatric surgery.
6. Discuss weight stigma and weight cycling as clinically consequential, evidence-grounded harms, and integrate this into a nonjudgmental clinical approach.

3. Scientific Foundations

3.1 Central energy-homeostasis neurobiology: the melanocortin system

Energy balance is coordinated principally by the arcuate nucleus (ARC) of the hypothalamus, which houses two functionally opposed neuron populations acting as a rheostat. POMC neurons are anorexigenic: activated, they release α-melanocyte-stimulating hormone (α-MSH), which binds melanocortin-4 receptors (MC4R) in the paraventricular hypothalamus to suppress appetite and — via sympathetic outflow to brown adipose tissue — increase thermogenesis and glucose uptake. AgRP neurons are orexigenic: their activation produces rapid, intense hunger, both by directly antagonizing α-MSH at MC4R and by releasing GABA to synaptically inhibit POMC neurons; AgRP can also silence downstream satiety neurons via Kir7.1 potassium channels independent of MC4R [1]. Mutations in POMC or MC4R are among the most common monogenic causes of severe early-onset obesity.

This system integrates peripheral signals. Leptin, secreted by adipocytes in proportion to fat mass, and insulin both activate POMC and inhibit AgRP neurons, providing a negative-feedback loop that should, in principle, cap adiposity. Ghrelin, secreted by the stomach, does the opposite, activating AgRP neurons and driving hunger. Gastrointestinal peptides — GLP-1, PYY, and CCK — signal satiety to the brain via the vagus nerve and circulation, and hypothalamic neurons directly sense circulating nutrients and these hormones to coordinate intake and expenditure [1][2]. Astrocytes and microglia in the ARC are increasingly recognized as active participants rather than bystanders: they express leptin receptors, sense lipids, and modulate the neuronal circuits that organize feeding [1]. This system also has a circadian architecture — POMC activity typically peaks in the active phase to prime satiety before rest — that can be disrupted by shift work and irregular meal timing [1].

3.2 Adipose tissue biology: white, brown, beige, and ectopic fat

Adipose tissue is not inert storage; it is the body's largest endocrine organ. White adipose tissue (WAT) stores triglycerides and secretes adipokines. Brown adipose tissue (BAT) performs non-shivering thermogenesis via UCP1-mediated mitochondrial uncoupling, dissipating chemical energy as heat rather than storing it; it is most abundant in infants and persists in defined depots in adults. Beige ("brite") adipocytes arise within white depots under cold or adrenergic stimulation and share BAT's thermogenic capacity [4]. BAT activity declines with aging and adiposity — a phenomenon termed "brown fat resistance" — and while cold exposure remains the most reliable activator, pharmacologic strategies (β3-agonists such as mirabegron) have shown inconsistent efficacy and cardiovascular safety concerns in humans; BAT activation is therefore best regarded as a promising metabolic adjunct rather than a proven weight-loss therapy [4].

The clinically decisive concept is the adipose expandability hypothesis: individuals have a finite, genetically and hormonally determined capacity to expand subcutaneous WAT safely. Once that capacity is exceeded, lipid "overflows" into visceral and ectopic depots — liver, pancreas, skeletal muscle, epicardium — producing hypertrophic, hypoxic adipocytes that recruit M1 macrophages into "crown-like structures" secreting TNF-α and IL-6 [3][5]. This explains why some individuals develop insulin resistance and type 2 diabetes at a comparatively low BMI, while others with high BMI remain metabolically healthy: adiposity distribution, not total mass, best predicts risk [3][6]. Epicardial adipose tissue, for example, can directly modulate myocardial fibrosis and stiffness, contributing to heart failure with preserved ejection fraction [6].

Adipokine and inflammatory signaling links this adipose dysfunction to systemic disease. Leptin and resistin are pro-inflammatory in excess; adiponectin is anti-inflammatory and insulin-sensitizing, and its levels fall as visceral adiposity rises. Pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, MCP-1) activate JNK and NF-κB pathways that impair insulin-receptor-substrate phosphorylation, driving systemic insulin resistance, hepatic steatosis, and eventually β-cell decompensation [42][44]. This inflammatory phenotype also appears to be epigenetically stabilized — for example, via hypermethylation of the adipogenic master regulator PPARγ — helping explain why metabolic dysfunction can persist even after some fat loss [44].

3.3 Leptin resistance, set point, and the biology of weight regain

In lean-to-obese transitions, the leptin–melanocortin axis itself becomes impaired: leptin's transport across the blood-brain barrier is progressively reduced, downstream JAK2/STAT3 signaling is blunted, and diet-induced hypothalamic neuroinflammation (activated microglia and astrocytes secreting TNF-α, IL-1β, IL-6) directly degrades leptin receptor function in the ARC — despite high circulating leptin levels [41][43]. This hypothalamic gliosis appears only partially reversible with weight loss, which is one mechanistic candidate for why the brain continues to "defend" a higher weight after diet-induced loss [43].

This defended-weight phenomenon is now well characterized empirically and is better described as a settling point within a defended range than a fixed set point: weight loss triggers a coordinated, multi-system response that actively promotes regain. Adaptive thermogenesis reduces total daily energy expenditure by 15–20% beyond what is predicted from lost body mass alone, via reduced basal metabolism, increased mitochondrial efficiency (up to 15–25% more ATP per unit of oxygen), reduced non-exercise activity thermogenesis (NEAT, by up to 35%), and a state of relative "functional hypothyroidism" (falling active T3, rising reverse T3) [7][8]. Simultaneously, gut-brain signaling shifts: ghrelin rises and remains elevated for at least 12 months, while GLP-1 and PYY fall, and sympathetic nervous system activity drops 20–40% in favor of parasympathetic, energy-storing tone [7]. Mouse models directly demonstrate persistent post-weight-loss hyperphagia proportional to the degree of prior weight gain [11]. Framed at a systems level, obesity can be modeled as a transition between alternative stable states (lean vs. obese) stabilized by reinforcing feedback loops — analogous to ecological regime shifts — making the reverse transition biologically effortful even when reduction is achieved [10]. Clinically, this predicts — and real-world data confirm — substantial regain after both intensive lifestyle programs and discontinuation of anti-obesity pharmacotherapy [7][9].

4. Clinical Relevance

Obesity is a primary driver of type 2 diabetes, atherosclerotic cardiovascular disease, obstructive sleep apnea (a ~4.4-fold increased prevalence), non-alcoholic fatty liver disease, several cancers, osteoarthritis, and depression [37][39]. Because it is now understood as a chronic, biologically defended disease rather than a discrete event to be "fixed," clinicians should treat it analogously to hypertension or diabetes: relapsing, requiring sustained management, and responsive to a portfolio of interventions rather than a single prescription. The clinician's practical task is threefold — set a differential expectation for percentage weight loss and its physiologic ceiling by modality; select and sequence dietary, pharmacologic, and surgical tools according to the patient's disease severity and preference (matching intensity to the guideline-based BMI/comorbidity thresholds below); and safeguard against the newer, drug-era harms of rapid, appetite-suppressed weight loss — namely, lean-mass and micronutrient depletion.

5. Evidence Review

Established (high confidence):

• Weight loss produces measurable metabolic adaptation (reduced energy expenditure beyond that predicted by body-composition change) and a hormonal profile that favors regain, and this state can persist for at least a year. AllNutrition evidence_strength: moderate, consensus_level: mixed [7][8][11].
• Adherence and total energy intake — not macronutrient ratio — are the dominant predictors of weight-loss success across low-carbohydrate, low-fat, and personalized-nutrition RCTs; low-carbohydrate and low-fat diets show comparable effects on inflammatory markers and adipokines. evidence_strength: strong, consensus: moderate [12][13][14][17][18][19].
• Semaglutide and tirzepatide produce clinically substantial weight loss (~15% and ~15–21% of body weight respectively in pivotal trials), primarily through appetite suppression and delayed gastric emptying, with gastrointestinal adverse effects as the dominant tolerability issue. evidence_strength: moderate–strong, consensus: moderate [27][28][33].
• Intermittent/time-restricted energy restriction is not superior to continuous energy restriction for weight loss or cardiometabolic markers when compared head-to-head. evidence_strength: strong, consensus: moderate [21][22].
• Bariatric surgery carries a well-documented, high-prevalence risk of micronutrient deficiency (vitamin D, iron, B12, zinc, folate), requiring lifelong monitoring and supplementation. evidence_strength: strong, consensus: moderate [34][35][36].

Probable:

• GLP-1/GIP receptor agonist therapy causes proportionally modest lean-mass loss (roughly 20–25% of total weight lost is lean tissue in trial substudies), and adequate protein intake (1.2–1.6 g/kg/day, higher in older or high-risk patients) plus resistance training likely mitigates this. evidence_strength: moderate, consensus: moderate [29][30][31][32].
• Ectopic and visceral fat, rather than total adiposity or BMI, best predict cardiometabolic risk (the "adipose expandability" model). evidence_strength: moderate, consensus: moderate [3][5][6].
• Structured, high-intensity behavioral programs (e.g., DiRECT-type very-low-calorie-diet primary-care protocols) can produce substantial type 2 diabetes remission (46% at one year in the trial setting), though real-world remission rates are considerably lower (4–18%) and durability depends on sustained weight maintenance. evidence_strength: strong, consensus: moderate [25][26].
• Weight stigma — including within healthcare encounters — is associated with worse mental health, disordered eating, diagnostic overshadowing, and reduced engagement with care. evidence_strength: moderate, consensus: moderate [45][46][47][48].

Emerging:

• Hypothalamic astrocyte and microglial gliosis as a structural, only partially reversible substrate for defended body weight and leptin resistance. evidence_strength: limited, consensus: moderate [41][43].
• Pharmacologic or nutritional strategies (e.g., weighted-vest "homeogravitational" loading, ketogenic-Mediterranean hybrid protocols) to blunt metabolic adaptation and preserve lean mass during aggressive weight loss. evidence_strength: moderate, consensus: mixed [7][8].
• Precision/personalized nutrition (genomic, microbiome-informed) for weight management shows only modest incremental benefit over standard advice and lacks a standardized framework. evidence_strength: moderate, consensus: mixed [18][19].

Controversial:

• Whether time-restricted eating exerts a circadian-mediated metabolic benefit independent of the caloric reduction it induces, versus being mechanistically no different from any other adherence-dependent energy-restriction strategy. evidence_strength: strong, consensus: mixed [21][22][24].
• Whether BMI-based staging should be replaced by clinical/preclinical-obesity or ABCD (Adiposity-Based Chronic Disease) frameworks in routine practice; guideline bodies are actively divided on operationalization. evidence_strength: moderate, consensus: mixed [39][40].

Unsupported/overstated:

• The claim that obesity is fundamentally a failure of willpower, or that any single "best diet" outperforms others once adherence and total energy intake are matched — both are contradicted by the comparative-diet literature [12][13][17][19].
• The assumption that a rigid, immutable numeric "set point" fully explains weight regulation; contemporary data better support a dynamically defended range shaped by hysteresis and reinforcing feedback, not a fixed thermostat [10][11].

6. Practical Clinical Applications

Dietary approaches for weight loss. No single macronutrient pattern is reproducibly superior for weight loss when calories and protein are equated; low-carbohydrate diets show modestly better short/medium-term weight loss and triglyceride/HDL effects, low-fat diets are equally effective when adherence is high, and the Mediterranean pattern has the strongest evidence for durable cardiometabolic and diabetes-prevention benefit, alongside comparable weight effects [12][14][15][16]. The clinical task is therefore to match the diet to the patient's preferences and metabolic phenotype (e.g., low-carbohydrate may suit patients with pronounced insulin resistance) and to explicitly counsel on the adherence literature, since the DIETFITS-type finding — that a "healthy low-fat" and "healthy low-carbohydrate" diet produce statistically similar average weight loss, with adherence explaining more variance than assignment — generalizes across the comparative-diet trial base [14][17][19].

Protein and satiety. Higher-protein intake (27–35% of energy, ~1.0–1.6 g/kg/day) improves satiety via increased GLP-1/PYY/CCK secretion and ghrelin suppression, has a higher thermic effect of food (20–30% vs. 5–10% for carbohydrate), and better preserves lean mass and resting energy expenditure during a deficit — an advantage of particular importance in older adults and in anyone using pharmacotherapy that suppresses appetite [2][17].

Very-low-calorie diets and remission. Structured VLCD-based programs (as in DiRECT) can produce substantial type 2 diabetes remission when weight loss is large and sustained, but medications that predispose to hypoglycemia (insulin, sulfonylureas) require prompt adjustment, and real-world remission is markedly lower than trial-level efficacy, underscoring the need for maintenance infrastructure [25][26].

Meal timing/intermittent fasting. Time-restricted eating and intermittent fasting produce weight loss roughly comparable to continuous energy restriction; benefit appears to derive mainly from spontaneous caloric reduction, though early (vs. late) eating windows and circadian alignment may confer modest additional metabolic benefit. These approaches are a reasonable adherence tool for patients who find continuous calorie counting burdensome, not a metabolically superior strategy per se [21][22][24].

Weight-loss maintenance. Multicomponent behavioral programs combining low-energy-density, high-fiber diets, protein prioritization (>1.3 g/kg/day), structured aerobic and resistance exercise, and self-monitoring produce the best maintenance outcomes; the National Weight Control Registry pattern (daily self-weighing, consistent meal patterns, ~1 hour/day of activity) exemplifies this evidence base [7].

GLP-1/GIP receptor agonists and nutrition co-management. Semaglutide and tirzepatide are now first-line pharmacotherapy for eligible patients, achieving weight loss (~15% and ~15–21% respectively) that approaches surgical results, plus cardiovascular risk reduction independent of weight change in some populations [27][28][33]. Because both drugs suppress intake enough to risk protein and micronutrient inadequacy (observed intakes as low as ~750 kcal and ~33 g protein/day in some cohorts), nutrition co-management should include: protein target 1.2–1.6 g/kg/day (up to 2.0 g/kg/day in older or high-sarcopenia-risk patients), 25–35 g protein per meal with a "protein-first" strategy, resistance training, a minimum energy floor (~1,200 kcal/day women, ~1,500 kcal/day men), fiber ~28 g/day, and monitoring for vitamin D, B12, calcium, magnesium, potassium, and iron deficiency [29][30][31][32]. When not to intensify: avoid aggressive caloric restriction stacked on top of GLP-1-induced anorexia; screen for disordered eating; adjust insulin/sulfonylurea doses proactively for hypoglycemia risk; and anticipate delayed gastric emptying implications for perioperative and anesthesia planning [28].

Bariatric surgery nutritional context. Roux-en-Y gastric bypass and sleeve gastrectomy remain the most effective durable interventions for severe obesity and type 2 diabetes remission (roughly half of patients by 2.5 years), but both require lifelong nutrient surveillance: near-universal risk of vitamin D deficiency, iron deficiency especially in menstruating women, B12 and folate deficiency from reduced intrinsic factor/gastric acid, and RYGB-specific zinc and copper risk. Guideline-based protocols specify high-potency multivitamins (>200% RDA), vitamin D ~3,000 IU/day, calcium citrate 1,200–1,500 mg/day, iron 45–60 mg/day, and structured lab monitoring at 1, 3, 6, and 12 months, then annually [25][34][35][36]. GLP-1 agonists are increasingly used adjunctively for suboptimal surgical weight loss or regain, but amplify these same nutritional risks and require intensified monitoring [34].

7. Clinical Pearls

• Weight regain after diet-induced loss is a predictable neuroendocrine event (rising ghrelin, falling GLP-1/PYY, reduced NEAT and T3), not a failure of discipline — say this explicitly to patients.
• "What diet?" matters less than "Can you sustain it?" — counsel toward the pattern the patient will actually follow, informed by the adherence literature.
• Any patient started on a GLP-1/GIP agonist needs a protein and resistance-training plan from day one, not after lean mass loss is noticed.
• BMI is a screening tool, not a diagnosis; visceral/ectopic fat distribution and functional status better predict cardiometabolic risk.
• Discontinuing incretin pharmacotherapy without a maintenance plan predictably produces substantial regain within a year — set this expectation before starting the drug, not after stopping it.
• Ask about weight-based experiences in prior healthcare encounters; diagnostic overshadowing is a documented, correctable failure mode.

8. Common Misconceptions

• "It's just calories in versus calories out, so all diets are equivalent for anyone." Total energy balance governs average outcomes, but metabolic adaptation, adherence, and individual phenotype (e.g., insulin resistance) meaningfully shape which approach a given patient can sustain and how their body composition responds [7][14].
• "Body weight has a fixed, unchangeable set point." The evidence better supports a defended range shaped by reinforcing hormonal and neural feedback (hysteresis), which is powerful but not immutable — hence why sustained behavioral, pharmacologic, and surgical interventions can and do shift outcomes [10][11].
• "Intermittent fasting has unique fat-burning magic beyond calorie restriction." Head-to-head trials show IF/TRE is not superior to matched continuous energy restriction for weight or most cardiometabolic markers [21][22].
• "GLP-1 drugs are a 'shortcut' that bypasses the need for nutrition counseling." These drugs increase, not decrease, the need for structured protein and micronutrient support given the anorexia they induce [29][31].
• "Weight regain after stopping a diet or drug means the patient failed." It reflects a return toward the biologically defended range once treatment pressure is removed — the same clinical framing used for hypertension medication discontinuation.

9. Summary

Obesity is a chronic disease sustained by a highly integrated, redundant neuroendocrine system — hypothalamic melanocortin circuits, leptin/insulin signaling, gut hormones, and a dysfunctional, ectopically distributing adipose organ — that actively defends elevated body fat and mounts a coordinated hormonal and metabolic response against weight loss. This biology explains the clinical reality that weight regain is the norm, not the exception, after both dietary and pharmacologic intervention, and it reframes obesity management from a single "prescription" to sustained, relapsing-disease-style care. Across the comparative-diet literature, adherence and total energy intake consistently outweigh macronutrient composition as predictors of weight-loss success, which should shape how clinicians counsel patients toward a sustainable rather than "optimal" diet. The arrival of highly effective GLP-1/GIP receptor agonist pharmacotherapy and the persistence of bariatric surgery as the most durable intervention have not eliminated the need for nutrition expertise — they have redirected it toward protecting lean mass, protein adequacy, and micronutrient status during aggressive, appetite-suppressed weight loss. Finally, weight stigma and weight cycling are not peripheral social concerns but evidence-documented clinical harms that should inform how every encounter about weight is conducted.

10. References

Ordered by evidence strength / relevance. Evidence level and AllNutrition trust score (0–1) as returned by the tool.

1. Neuronal control of peripheral insulin sensitivity and glucose metabolism. Nature Communications (2017). Review — trust 0.69.
2. Omega-6 and omega-3 fatty acids in feeding behavior: Biological mechanisms and implications for dietary adherence. A mini-review. Neuroscience and Biobehavioral Reviews (2026). Review — trust 0.762.
3. Adipose tissue distribution in metabolic disease: depot-specific biology, clinical assessment, and therapeutic remodeling. Frontiers in Endocrinology (2026). Review — trust 0.60.
4. Comparative anatomy and metabolic profiles of brown and white adipose tissue in humans. Frontiers in Endocrinology (2026). Review — trust 0.73.
5. Type 2 diabetes as a disease of progressive loss of individual adipose storage capacity. Medical Hypotheses (2026). Observational — trust 0.598.
6. Immunometabolic Organ Crosstalk in Heart Failure with Preserved Ejection Fraction: The Role of Dietary Patterns in Obesity-Related Inflammation. Nutrients (2026). Review — trust 0.833.
7. Metabolic Adaptation and Weight Regain in Obesity Treatment: The Central Role of Nutrition in the Era of Bariatric Surgery and GLP-1-Based Pharmacotherapy. Nutrients (2026). Review — trust 0.883.
8. Beyond GLP-1 Agonists: An Adaptive Ketogenic–Mediterranean Protocol to Counter Metabolic Adaptation in Obesity Management. Nutrients (2025). Review — trust 0.663.
9. Turning obesity into an iatrogenic disease? Clinical Nutrition ESPEN (2026). Review — trust 0.65.
10. Asymmetric responses to resource overload: a bow-tie perspective on lake eutrophication and human obesity. Theory in Biosciences (2026). Review — trust 0.613.
11. Evidence of persistent hunger following dietary weight loss in mice. iScience (2026). Observational — trust 0.787.
12. Carbohydrate-restricted diet types and macronutrient replacements for metabolic health in adults: A meta-analysis of randomized trials. Clinical Nutrition (2025). Systematic review — trust 0.857.
13. Comparable effects of low-carbohydrate and low-fat diets on inflammatory markers and adipokines: A systematic review and meta-analysis of randomized trials. Nutrition Research (2026). Systematic review — trust 0.837.
14. Effects of different nutritional interventions on abdominal adiposity components and metabolic parameters. Nutrition (2025). RCT — trust 0.835.
15. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. British Journal of Nutrition (2013). Systematic review — trust 0.627.
16. Effect of Carbohydrate-Restricted Diets and Intermittent Fasting on Obesity, Type 2 Diabetes Mellitus, and Hypertension Management: Consensus Statement (Korean Society for the Study of Obesity et al.). Diabetes & Metabolism Journal (2022). Guideline — trust 0.755.
17. Planetary Health Diet Adherence Improves Weight and Body Composition During Energy Restriction. Obesity (2026). RCT — trust 0.75.
18. Effects of personalized nutrition on cardiometabolic biomarkers in adults with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. Nutrition & Metabolism (2026). Systematic review — trust 0.818.
19. Precision nutrition and chronic disease: Integrating genomics, microbiome, and digital health for personalized dietary interventions. Clinical Nutrition ESPEN (2026). Review — trust 0.60.
20. Evaluation of the effectiveness of a restricted diet therapy package combining standardised caloric intake with exercise in obese patients: A 12-month randomised controlled trial. Clinical Nutrition (2025). RCT — trust 0.85.
21. Effectiveness of Intermittent Fasting and Time-Restricted Feeding Compared to Continuous Energy Restriction for Weight Loss. Nutrients (2019). Review — trust 0.90.
22. Effects of Intermittent Energy Restriction Compared with Those of Continuous Energy Restriction on Body Composition and Cardiometabolic Risk Markers – A Systematic Review and Meta-Analysis of RCTs. Advances in Nutrition (2023). Systematic review — trust 0.912.
23. Comparing caloric restriction regimens for effective weight management in adults: a systematic review and network meta-analysis. International Journal of Behavioral Nutrition and Physical Activity (2024). Systematic review — trust 0.835.
24. Time-restricted eating and metabolic health: implications for nutritional strategies and weight loss. Frontiers in Nutrition (2026). Review — trust 0.688.
25. Economic Evaluation of NHS England's Type 2 Diabetes Path to Remission Pilot Scheme. PharmacoEconomics - Open (2025). Observational — trust 0.758.
26. Six-year Follow-Up of Nonpharmacological and Nonsurgical Obesity Treatments. Diabetes, Metabolic Syndrome and Obesity (2026). Observational — trust 0.752.
27. Tirzepatide and semaglutide: different twins? European Heart Journal Supplements (2026). Review — trust 0.677.
28. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory (ACLM, ASN, OMA, The Obesity Society). Obesity Pillars (2026). Guideline — trust 0.675.
29. Optimizing Weight Loss in the GLP-1 Era: Preserving Muscle Mass, Function and Metabolic Health Through Precision Nutrition and Resistance Training. Pharmaceuticals (2026). Review — trust 0.90.
30. Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies. Metabolites (2026). Review — trust 0.775.
31. Avoiding malnutrition in the era of GLP-1 medications: emerging evidence and opportunities for integrated nutrition care. The Journal of Nutrition (2026). Review — trust 0.833.
32. Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity. Nutrients (2026). Review — trust 0.75.
33. Tirzepatide and Cardiometabolic Effects in Obese Non-diabetic Adults: A Systematic Review, Meta-Analysis, and Narrative Synthesis. Cureus (2026). Systematic review — trust 0.762.
34. Micronutrient Deficiencies in Obese Patients and Risk of Postoperative Fistula: A Forgotten Link in Bariatric and Metabolic Surgery. Nutrients (2026). Review — trust 0.715.
35. Zinc status following different bariatric procedures: systematic review and meta-analysis. Annals of Medicine (2026). Systematic review — trust 0.842.
36. Micronutrient status after Roux-en-Y gastric bypass in patients receiving intensive postoperative nutrition education. Nutrition (2026). Observational — trust 0.77.
37. From obesity to cardiovascular disease: pathological basis and clinical implications. The American Journal of Medicine (2026). Review — trust 0.765.
38. Guideline for the Management of Obesity in Adult Patients with Obstructive Sleep Apnea. Korean Society of Sleep and Breathing (2026). Guideline — trust 0.805.
39. Update on Obesity and Its Relationship to Atherosclerotic Cardiovascular Disease and Associated Risk Factors. Nutrients (2026). Review — trust 0.613.
40. Emerging classifications of cardiometabolic risk in obesity. Archivos de Cardiología de México (2026). Review — trust 0.742.
41. Metabolic Inflammation At The Adipose Brain Axis. Frontiers in Physiology (2026). Review — trust 0.713.
42. White adipose tissue expansion as the driver of insulin resistance and secondary endocrine disturbances in obesity. Diabetology & Metabolic Syndrome (2026). Review — trust 0.725.
43. Microbiota–gut–brain axis dysregulation in obesity: Neuroimmune-endocrine mechanisms and precision therapeutic targets. Obesity Medicine (2026). Review — trust 0.73.
44. Synergistic Impact of Obesity and PCOS on Immune Dysregulation: A Review of Systemic and Local Inflammatory Profiles. International Journal of Women's Health (2026). Review — trust 0.863.
45. Exploring Strategies for Addressing Weight Stigma: An Analysis of Health Communication Dynamics and Evolutionary Themes. British Journal of Hospital Medicine (2026). Observational — trust 0.752.
46. Drugs, diet, or surgery? How treatment type and willpower shape responsibility for weight loss and judgments of the physician and treatment. Frontiers in Psychology (2026). Observational — trust 0.722.
47. Psychosocial determinants of food cravings in women with overweight and obesity: self-stigmatisation, weight bias and self-esteem. BMC Psychology (2026). Observational — trust 0.637.
48. Mapping weight stigma in food-based dietary guidelines across thirteen countries in Latin America and the Caribbean. The Lancet Regional Health - Americas (2026). Observational — trust 0.813.

Supporting sources also surfaced: Hypothalamic astrocytes: connecting brain and periphery in metabolic control (Reviews in Endocrine and Metabolic Disorders 2025, review, trust 0.708); Hypothalamic actions of estrogens in the regulation of energy and glucose homeostasis (Reviews in Endocrine and Metabolic Disorders 2025, review, trust 0.838); From diet to hypothalamic dysfunction: microbiota-hypothalamus-adipose axis (Reviews in Endocrine and Metabolic Disorders 2026, review, trust 0.825); Adipose tissue catecholamine resistance (Metabolism 2026, review, trust 0.733); Obesity is always a clinically relevant chronic disease (Eating and Weight Disorders 2026, observational, trust 0.69); TRE versus dietetic guidance on glycaemic outcomes (Diabetologia 2026, RCT, trust 0.853); Prospective Association Between Weight Variability and Subsequent Long-Term Weight Loss, CALERIE Study (Obesity 2026, RCT, trust 0.738); Adiponectin: A potential therapeutic target for metabolic syndrome (Cytokine and Growth Factor Reviews 2018, review, trust 0.655).